ACR 2022
How Does Risk for CV Events Differ Between Tofacitinib and TNFi in RA?
Results of the ORAL Surveillance study showed a higher risk for major adverse CV events and venous thromboembolism with tofacitinib vs TNFis.
Your search for tofacitinib returned 40 results
DDW 2022
Tofacitinib, Vedolizumab Effective for UC Post-Anti-TNF Agent Failure
Researchers compared the effectiveness of tofacitinib and vedolizumab among patients with UC who had experienced anti-TNF failure.
News
CV, Cancer Risk Up With Tofacitinib for Rheumatoid Arthritis
Incidences of major adverse cardiovascular events, cancers higher with tofacitinib versus TNF inhibitor; criteria for noninferiority not met
ACR 2019, News
Few Serious Infections in Offspring Exposed to Non-TNFi Biologics, Tofacitinib
Researchers compared the risk for serious infections in offspring of mothers with chronic inflammatory diseases who received non-TNFi biologics or tofacitinib during pregnancy vs offspring who were unexposed, but exposed to TNFi in utero.
Musculoskeletal Disorders
Tofacitinib Benefits Sustained for Two Years in Patients With RA
The clinical benefits of tofacitinib in combination with methotrexate are sustained over 2 years among patients with rheumatoid arthritis (RA), according to a study published online January 22 in Arthritis & Rheumatology.
ACR/ARHP 2018 Annual Meeting
Venus Thromboembolism Risk Assessed With Tofacitinib, TNF Inhibitors
Although the incidence rate of venous thromboembolism was numerically higher in patients treated with tofacitinib vs TNF inhibitors, the risk was not statistically significant.
ACR/ARHP 2018 Annual Meeting
RA Remission Compared for Tofacitinib Alone vs. Steroid Plus Tofacitinib Tx
The results support combination therapy with intra-articular steroid injections and tofacitinib to achieve clinical and radiographic remission in patients with early rapid radiographic progression RA.
ACR/ARHP 2018 Annual Meeting
Clinical Efficacy of Tofacitinib Once-Daily vs Twice-Daily Examined in RA
Tofacitinib extended release has comparable clinical efficacy to tofacitinib administered twice daily.
News
Tofacitinib + Phototherapy May Be Beneficial for Vitiligo Treatment
Case reports describe repigmentation of vitiligo with facial involvement in Hispanic woman, white man
News
Tofacitinib Efficacy Investigated in Patients With Psoriatic Arthritis
Tofacitinib is superior for patients with inadequate response to TNF inhibitors or conventional DMARDs
